Quantcast

Latest Vanda Pharmaceuticals Inc. Stories

2014-07-17 20:23:15

Conference Call and Webcast to Follow WASHINGTON, July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the second quarter of 2014 on Thursday, August 7, 2014, before the market opens. The Company will host a conference call at 10:00 AM ET on Thursday, August 7, 2014,...

2014-06-03 08:31:35

WASHINGTON, June 3, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ(TM) (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). "The EMA submission is an important milestone towards providing a treatment option for people living with Non-24 in the European Union," said Mihael...

2014-06-02 20:22:55

WASHINGTON, June 2, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) will present additional data from its HETLIOZ(TM) (tasimelteon) clinical development program at SLEEP 2014, the 28th Annual Meeting of Associated Professional Sleep Societies in Minneapolis, Minnesota. HETLIOZ(TM) data at SLEEP 2014 will be presented in one oral and six poster sessions. The data presentation schedule is as follows: Oral Presentation -- June 4(th) at 2:15 - 2:30pm, Assessment of...

2014-05-29 20:23:09

Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON, May 29, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2014 at 10:30 a.m. Eastern Time. The...

2014-05-08 08:32:11

WASHINGTON, May 8, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2014. Key Highlights: -- On January 31, 2014, Vanda announced that the U.S. Food and Drug Administration (FDA) approved HETLIOZ(TM) (tasimelteon) 20mg...

2014-04-24 20:23:02

Conference Call and Webcast to Follow WASHINGTON, April 24, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the first quarter of 2014 on Thursday, May 8, 2014, before the market opens. The Company will host a conference call at 10:00 AM ET on Thursday, May 8, 2014, during...

2014-04-09 20:22:14

Vanda launches HETLIOZSolutions(TM), a patient resource for information and access to HETLIOZ(TM) WASHINGTON, April 9, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.( )...

2014-02-28 08:25:02

The Non-24 Share More Campaign aims to educate totally blind people living with the disorder and their families through its health and wellness podcast series WASHINGTON, Feb. 28, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and launch the expert podcast series available at...

2014-02-13 08:30:20

WASHINGTON, Feb. 13, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2013. "The recent FDA approval of HETLIOZ(TM) marks an important advancement in the treatment of Non-24," said Mihael H. Polymeropoulos, M.D., Vanda's...

2014-01-31 16:23:11

Non-24 is highly prevalent among the totally blind WASHINGTON, Jan. 31, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ(TM) (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ(TM) is the first FDA approved medication for Non-24. Non-24 was first described more than 60 years ago, and is a chronic, circadian rhythm disorder...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related